A Prospective, Multicenter, Open-label, Phase IV, Interventional Study to Assess the Safety and Efficacy of Capmatinib in Indian Patients With Mesenchymalepithelial Transition (MET) Exon 14 Skipping Mutation Positive Advanced Nonsmall Cell Lung Cancer (NSCLC).
Latest Information Update: 06 May 2024
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 26 Apr 2024 Planned End Date changed from 1 Jul 2024 to 30 Jun 2025.
- 26 Apr 2024 Planned primary completion date changed from 1 Jul 2024 to 30 Jun 2025.
- 21 Sep 2022 Status changed from not yet recruiting to recruiting.